The Manufacturers Life Insurance Company Makes New Investment in ICU Medical, Inc. $ICUI

The Manufacturers Life Insurance Company bought a new stake in ICU Medical, Inc. (NASDAQ:ICUI) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 195,442 shares of the medical instruments supplier’s stock, valued at approximately $28,652,000. The Manufacturers Life Insurance Company owned about 0.78% of ICU Medical at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Norges Bank acquired a new position in shares of ICU Medical in the fourth quarter valued at approximately $58,083,000. Kirr Marbach & Co. LLC IN boosted its position in ICU Medical by 18.4% during the 1st quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock worth $5,702,000 after buying an additional 6,863 shares during the period. F m Investments LLC boosted its position in ICU Medical by 33.3% during the 4th quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock worth $6,637,000 after buying an additional 11,608 shares during the period. Thrivent Financial for Lutherans grew its holdings in ICU Medical by 1,604.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after acquiring an additional 285,648 shares during the last quarter. Finally, Reinhart Partners LLC. bought a new stake in ICU Medical during the 2nd quarter worth approximately $46,148,000. 96.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Sanford C. Bernstein cut shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Raymond James Financial reiterated a “strong-buy” rating and set a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. Wall Street Zen upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Finally, Piper Sandler lifted their target price on ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $192.80.

ICU Medical Stock Performance

NASDAQ:ICUI opened at $175.10 on Friday. The company has a market capitalization of $4.38 billion, a PE ratio of 148.39, a P/E/G ratio of 2.27 and a beta of 0.74. The company has a 50 day simple moving average of $163.95 and a two-hundred day simple moving average of $143.89. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. ICU Medical, Inc. has a fifty-two week low of $112.50 and a fifty-two week high of $192.85.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same quarter in the previous year, the company earned $2.10 EPS. The company’s revenue for the quarter was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Research analysts anticipate that ICU Medical, Inc. will post 7.19 earnings per share for the current year.

Insider Activity

In related news, COO Christian B. Voigtlander sold 8,929 shares of ICU Medical stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the completion of the transaction, the chief operating officer owned 37,377 shares of the company’s stock, valued at $6,837,374.61. This trade represents a 19.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elisha W. Finney sold 378 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total transaction of $68,977.44. Following the completion of the transaction, the director owned 4,871 shares in the company, valued at approximately $888,860.08. The trade was a 7.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 16,974 shares of company stock worth $3,085,844 over the last ninety days. Corporate insiders own 2.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.